Medicis Pharmaceutical Corp

Medicis Pharmaceutical — Merger or Acquisition (September 2012)

17 slides from Medicis Pharmaceutical's merger presentation, Sep 5, 2012

  1. Slide 1: Communication Plan

    Communication Plan Exhibit 99.2

  2. Slide 2: Who is Valeant?

    Who is Valeant?

  3. Slide 3: Valeant Overview

    Valeant Overview Focused, multinational specialty pharma company $2.4B in 2011 revenue and ~7,000 employees Headquartered in Montreal, Canada (NYSE/TSX: VRX) International footprint Specialty Pharma (U.S., Canada, Australia, New Zealand) Branded Generics – Central and Eastern Europe; Latin America;

  4. Slide 4: Highly Complementary Dermatology Portfolio

    Highly Complementary Dermatology Portfolio Topical Acne Oral Acne Actinic Keratosis Dermatitis OTC Anti-Viral Anti-Fungal Single Agent Imiquimod Product 5FU Product Non-Steroidal Steroidal Combination Agent

  5. Slide 5: Complementary Aesthetic Portfolio

    Complementary Aesthetic Portfolio Collagen Stimulator Dermal Filler Botulinium Toxin Physician dispensed

  6. Slide 6: Comprehensive Late Stage Pipeline

    Comprehensive Late Stage Pipeline Late Stage Pipeline Medicis Novel LCM Aesthetics Dermatitis A. Keratosis Acne Anti-Fungal OTC

  7. Slide 7: Valeant Pipeline

    Valeant Pipeline

  8. Slide 8: Valeant-Financial Information

    Valeant-Financial Information

  9. Slide 9: Talking Points by Audience

    Talking Points by Audience

  10. Slide 10: Audiences

    Audiences Employees Headquarters Commercial team Investors Physicians Alliance Partners Vendors

  11. Slide 11: Employee Talking Points JS & CCOM

    Employee Talking Points JS & CCOM Terms of the transaction signed on Sunday September 2nd VRX to Merge with Medicis for $44 per share The combination of our two highly complementary product portfolios under the Medicis name will allow us to accelerate our efforts to drive sales, establish best-in-cl

  12. Slide 12: Employee Talking Points Field Sales

    Employee Talking Points Field Sales VRX to Merge with Medicis for $44 per share The combination of our two highly complementary product portfolios under the Medicis name will allow us to accelerate our efforts to drive sales, establish best-in-class commercial and R&D operations, and serve the consu

  13. Slide 13: Jonah's Voicemail Script

    Jonah’s Voicemail Script Good morning. This is Jonah Shacknai, Chairman and CEO and I have some important news to share with you. Just minutes ago, Medicis announced the signing of a merger agreement where Valeant Pharmaceuticals would acquire Medicis, creating a combined company that will be a glob

  14. Slide 14: Investors

    Investors Talking points for IR teams Terms of the transaction signed on Sunday September 2nd VRX to Merge with Medicis for $44 per share The combination of our two highly complementary product portfolios under the Medicis name will allow us to accelerate our efforts to drive sales, establish best-i

  15. Slide 15: Physicians

    Physicians Talking points for the commercial team VRX to Merge with Medicis Combined commercial operations, as Medicis, will be located in Scottsdale, AZ This combination of two highly complementary product portfolios under the Medicis name will allow us to better serve medical and aesthetic dermato

  16. Slide 16: Alliance Partners

    Alliance Partners Terms of the transaction signed on Sunday September 2nd VRX to Merge with Medicis for $44 per share Combined commercial operations will be located in Scottsdale, AZ R&D will be in Scottsdale and Petaluma (No. California) Corporate functions will be located in NJ Will take time to o

  17. Slide 17: Vendors

    Vendors Dear XXXX, Medicis announced on September 3, 2012 its intent to combine with Valeant Pharmaceuticals International, Inc. (“Valeant”). As currently contemplated by the parties, the combined commercial operations, as Medicis, will be located in Scottsdale, AZ. After closing, the combined entit

Medicis Pharmaceutical — Merger or Acquisition (September 2012) on 6ix